Ozempic Goes Generic —But Not in the US
A drug that helped turn Novo Nordisk into Europe’s most valuable company is about to lose its…
Coming Soon: ‘Wegovy HD’
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may…
Ozempic Manufacturer Warned by FDA for Failing to Report Potential Side Effects
Packaging for the Ozempic injectable penCredit: Mario Tama/Getty NEED TO KNOW The FDA sent a “warning letter” to…
The Best Healthcare Stocks to Buy With $50 Right Now
It’s not hard to find healthcare stocks, including small-cap biotech companies, trading below $50 per share. However, many…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
Weight-loss wegovy jab may carry greater risk of sudden sight loss, study finds – The Irish Times
Patients taking Wegovy have nearly five times the risk of sudden sight loss compared with those on Ozempic,…
Hims & Hers abandons plan for cheaper Wegovy knockoff after FDA warning
Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy…
Hims & Hers will sell real Ozempic in deal with Novo Nordisk
Hims & Hers and the Danish pharma giant Novo Nordisk have ended a bitter legal feud that will…
2 Healthcare Stocks That Are Too Cheap to Ignore
Some indicators suggest that equity markets are currently overvalued. For instance, the S&P 500 Shiller CAPE ratio is…
FDA warns Novo Nordisk over unreported potential Ozempic side effects
Novo Nordisk, the pharmaceutical company behind Ozempic, has received a warning letter from the U.S. Food and Drug…
The era of $199 copycat weight loss drugs is ending — and it could cost patients
After two splashy Super Bowl commercials focused on making weight loss medication more accessible, Hims & Hers will…